April 28, 2016
Authored and Edited by David C. Seastrunk; Elliot C. Cook; Daniel F. Klodowski; Aaron L. Parker
In the 63 Final Written Decisions issued by the Patent Trial and Appeal Board in March, the Board cancelled 559 (65.00%) of the instituted claims and declined to cancel 251 (29.19%) of the instituted claims. Patent owners conceded 50 (5.81%) of the instituted claims through motions to amend or disclaimer. These numbers are considerably better for patentees than the February 2016 numbers, where 79.45% of all instituted claims were cancelled and only 18.12% of instituted claims survived.

On a per-case basis, no instituted or substitute claims survived in 42 (66.67%) of the decisions, all instituted claims survived in 18 (28.57%) of the decisions, and a mixed outcome occurred in 3 (4.76%) of the decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision. These numbers are also significantly more favorable to patentees than the February 2016 numbers, where no instituted claims survived in 82.86% of cases and all instituted claims survived in only 5.71% of cases.

The following resources are also available on the AIA Blog:
Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.